Comparing subcutaneous and sublingual immunotherapy: What do we know?

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 6, 2012, Pages 640-647

  Bahceciler, Nerin N ^a   Galip, Nilufer ^a  

^a NEAR EAST UNIVERSITY   (Turkey)

Author keywords

Allergic rhinitis; Asthma; Specific allergen immunotherapy; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

IMMUNOGLOBULIN G4; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC DISEASE; ANTIBODY RESPONSE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TREATMENT RESPONSE;

ADMINISTRATION, SUBLINGUAL; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; RHINITIS, ALLERGIC, PERENNIAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871292626     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328358d5f2     Document Type: Review

References (63)

1. Akdis M, Akdis CA. Mechanisms of allergen specific immunotherapy. J Allergy Clin Immunol 2007; 119:780-791
2. Larche M, Akdis CA, Valenta R. Immuological mechanisms of allergenspecific immunotherapy. Nat Rev Immunol 2006; 6:761-771
3. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010:CD001186.
4. Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL conseensus report. Allergy 2008; 63:5-34
5. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2005; 115:676-684
6. Till SJ, Francis JN, Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-1034
7. Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2:814-817
8. Roberts G, Hurley C, Turcanu V, Lach G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117:263-268
9. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: a systematic review and meta-analysis. Allergy 2005; 60:4-12
10. Frew AJ, Powell RJ, Corrigan CJ. Durham SR efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325
11. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-440
12. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:133813-133845
13. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007: CD001936.
14. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119:881-891
15. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151:969-974
16. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:1022-1041
17. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000:CD001186.
18. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003:CD001186.
19. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-148
20. Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609
21. Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162-1172
22. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64:1570-1579
23. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809
24. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-190
25. Wahn U, Tabar A, Kuna P, et al., SLIT Study Group. Efficacy and safety of 5-grass-ollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160-166
26. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009; 64:179-186
27. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-173
28. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17: 408-415
29. Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007; 18:47-57
30. Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009; 123:763-769
31. Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 2012; 130:215-224
32. ouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-3259
33. Van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163: 2944-2952
34. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-1208
35. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-1214
36. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-4666
37. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317:71-79
38. Strobel S, Mowat AM. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998; 19:173-181
39. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254-260
40. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-1125
41. Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-2898
42. Radulovic S, Jacobson MR, Durham SR, et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-1472
43. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-roducing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713
44. O'Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180: 936-947
45. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606
46. Zimmer A, Bouley J, Le Mignon M, et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol 2012; 129:1020-1030
47. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81:401-405
48. Passalacqua G, Bagnasco M, Mariani G, et al. Local immunotherapy: pharmacokinetics and efficacy. Allergy 1998; 53:477-484
49. Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-374
50. Allam JP, Novak N. Local immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11:571-578
51. Jacobsen L, Niggemann B, Dreborg S, et al., The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-948
52. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201
53. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-725
54. Durham SR. GT-08 investigators. Sustained effects of grass pollen AIT. Allergy 2011; 66 (Suppl 95):50-52
55. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126:969-975
56. Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:45-53
57. Bernardis P, Agnoletto M, Puccinelli P, et al. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol 1996; 6:55-62
58. Mungan D, Misirligil Z, Gu? rbu? z L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82:485-490
59. Quirino T, Iemoli E, Siciliani E, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26:1253-1261
60. Antú nez C, Mayorga C, Corzo JL, et al. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy: comparison with subcutaneous administration. Pediatr Allergy Immunol 2008; 19:210-218
61. Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288-298
62. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/ rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922-932
63. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergenspecific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011; 128:808-815